skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: ClinicalKey remover idioma: Russo remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Baselga, José, Dr ; Bradbury, Ian, PhD ; Eidtmann, Holger, MD ; Di Cosimo, Serena, MD ; de Azambuja, Evandro, MD ; Aura, Claudia, MD ; Gómez, Henry, MD ; Dinh, Phuong, MD ; Fauria, Karine, PhD ; Van Dooren, Veerle, MSc ; Aktan, Gursel, MD ; Goldhirsch, Aron, MD ; Chang, Tsai-Wang, MD ; Horváth, Zsolt, MD ; Coccia-Portugal, Maria, MD ; Domont, Julien, MD ; Tseng, Ling-Min, MD ; Kunz, Georg, MD ; Sohn, Joo Hyuk, MD ; Semiglazov, Vladimir, MD ; Lerzo, Guillermo, MD ; Palacova, Marketa, MD ; Probachai, Volodymyr, MD ; Pusztai, Lajos, DPhil ; Untch, Michael, PhD ; Gelber, Richard D, PhD ; Piccart-Gebhart, Martine, PhD

The Lancet (British edition), 2012-02, Vol.379 (9816), p.633-640 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Gianni, Luca, Dr ; Eiermann, Wolfgang, MD ; Semiglazov, Vladimir, MD ; Manikhas, Alexey, MD ; Lluch, Ana, MD ; Tjulandin, Sergey, MD ; Zambetti, Milvia, MD ; Vazquez, Federico, MD ; Byakhow, Mikhail, MD ; Lichinitser, Mikhail, MD ; Climent, Miguel Angel, MD ; Ciruelos, Eva, MD ; Ojeda, Belén, MD ; Mansutti, Mauro, MD ; Bozhok, Alla, MD ; Baronio, Roberta, MSci ; Feyereislova, Andrea, MD ; Barton, Claire, MD ; Valagussa, Pinuccia ; Baselga, Jose, MD

The Lancet (British edition), 2010-01, Vol.375 (9712), p.377-384 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
Material Type:
Artigo 		Adicionar ao Meu Espaço

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole

Rose, C. ; Vtoraya, O. ; Pluzanska, A. ; Davidson, N. ; Gershanovich, M. ; Thomas, R. ; Johnson, S. ; Caicedo, J.J. ; Gervasio, H. ; Manikhas, G. ; Ben Ayed, F. ; Burdette-Radoux, S. ; Chaudri-Ross, H.A. ; Lang, R.

European journal of cancer (1990), 2003-11, Vol.39 (16), p.2318-2327 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Cortes, Javier, MD ; O'Shaughnessy, Joyce, MD ; Loesch, David, MD ; Blum, Joanne L, MD ; Vahdat, Linda T, MD ; Petrakova, Katarina, MD ; Chollet, Philippe, MD ; Manikas, Alexey, MD ; Diéras, Veronique, MD ; Delozier, Thierry, MD ; Vladimirov, Vladimir, MD ; Cardoso, Fatima, MD ; Koh, Han, MD ; Bougnoux, Philippe, MD ; Dutcus, Corina E, MD ; Seegobin, Seth, MSc ; Mir, Denis, MSc ; Meneses, Nicole, MSHS ; Wanders, Jantien, MD ; Twelves, Chris, Prof

The Lancet (British edition), 2011-03, Vol.377 (9769), p.914-923 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

Diel, I.J ; Body, J.-J ; Lichinitser, M.R ; Kreuser, E.D ; Dornoff, W ; Gorbunova, V.A ; Budde, M ; Bergström, B

European journal of cancer (1990), 2004-07, Vol.40 (11), p.1704-1712 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Enhanced ex vivo apoptosis of peripheral granulocytes is a sufficient factor of neutropenia following myeloablative chemotherapy
Enhanced ex vivo apoptosis of peripheral granulocytes is a sufficient factor of neutropenia following myeloablative chemotherapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Enhanced ex vivo apoptosis of peripheral granulocytes is a sufficient factor of neutropenia following myeloablative chemotherapy

Chukhlovin, Alexei

Leukemia research, 2000-06, Vol.24 (6), p.507-509 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.